BioWorld

Sep. 23, 2005

View Archived Issues

Private Deal Brings $31M To Memory For Research

Months after losing part of a partnership, Memory Pharmaceuticals Corp. extended its runway through the end of next year by raising about $31 million in gross proceeds through a private stock and warrant placement. (BioWorld Today) Read More

Investors: Regulatory Rules Make Exit Paths Expensive

Read More

Snail's Cancer Role Expands From Metastasis To Relapse

Read More

CytRx Starting Phase II With Arimoclomol In ALS Patients

Read More

FDA Request Delays Decision On Avanir's Neurodex In PBA

Read More

Other News To Note

Read More